Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TPSAB1 | Q15661 | 9/20 | 0.48 |
| ▸ | TPSD1 | Q9BZJ3 | 9/20 | 0.48 |
| ▸ | TPSG1 | Q9NRR2 | 9/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7421428 | 1.00 | HPGD (0.54) | HPGDEPHX1USP2SMN1; SMN2TPSAB1 | |
| SCHEMBL22354690 | 0.95 | EPHX1 (0.57) | HPGDEPHX1USP2SMN1; SMN2TPSAB1 | |
| SCHEMBL7530498 | 0.94 | HPGD (0.49) | HPGDEPHX1USP2SMN1; SMN2TPSAB1 | |
| SCHEMBL7530505 | 0.94 | HPGD (0.49) | HPGDEPHX1USP2SMN1; SMN2TPSAB1 | |
| SCHEMBL27253412 | 0.83 | HPGD (0.44) | HPGDEPHX1USP2SMN1; SMN2RECQL | |
| SCHEMBL21456062 | 0.83 | HPGD (0.58) | HPGDEPHX1USP2SMN1; SMN2RECQL | |
| SCHEMBL15559576 | 0.82 | HRH3 (0.57) | — | |
| SCHEMBL2217468 | 0.81 | HPGD (0.53) | HPGDEPHX1USP2SMN1; SMN2RECQL | |
| SCHEMBL18294 | 0.81 | USP2 (0.69) | HPGDEPHX1USP2SMN1; SMN2RECQL | |
| SCHEMBL698803 | 0.81 | USP2 (0.69) | HPGDEPHX1USP2SMN1; SMN2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8669266-B2 | Quinoline-carboxamide derivatives as P2Y12 antagonists | SANOFI (FR) | 2014-03-11 | — | — | US | disclosed |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-2148871-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008128647-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | P2RY12, P2RY1, P2RY2 | HPGD 1458/4885EPHX1 428/4885USP2 4107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.